TORC1 Is Essential for NF1-Associated Malignancies

Current Biology

Volumn 18, Issue 1, 2008, Pages 56-62

  Johannessen, Cory M ^a,b,c   Johnson, Bryan W ^a,b,c   Williams, Sybil M Genther ^a,c   Chan, Annie W ^c,d   Reczek, Elizabeth E ^a,c   Lynch, Ryan C ^c,e   Rioth, Matthew J ^c,e   McClatchey, Andrea ^c   Ryeom, Sandra ^c,e   Cichowski, Karen ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

CELLCYCLE; SIGNALING

Indexed keywords

CYCLIN D; CYCLINE; HIF1A PROTEIN, MOUSE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; RAPAMYCIN; TORC1 PROTEIN, MOUSE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL; ARTICLE; C57BL MOUSE; CELL LINE; DISEASE MODEL; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE; NEOPLASM; PHYSIOLOGY; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL LINE; CYCLINS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GENES, NEUROFIBROMATOSIS 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIROLIMUS; TRANSCRIPTION FACTORS;

MAMMALIA; MURINAE;

EID: 44449093081     PISSN: 09609822     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cub.2007.11.066     Document Type: Article

References (26)

1. Ferner R.E., Huson S.M., Thomas N., Moss C., Willshaw H., Evans D.G., Upadhyaya M., Towers R., Gleeson M., Steiger C., et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J. Med. Genet. 44 (2007) 81-88
2. Martin G.A., Viskochil D., Bollag G., McCabe P.C., Crosier W.J., Haubruck H., Conroy L., Clark R., O'Connell P., Cawthon R.M., et al. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell 63 (1990) 843-849
3. Sabatini D.M. mTOR and cancer: Insights into a complex relationship. Nat. Rev. Cancer 6 (2006) 729-734
4. Tonsgard J.H. Clinical manifestations and management of neurofibromatosis type 1. Semin. Pediatr. Neurol. 13 (2006) 2-7
5. Dasgupta B., Yi Y., Chen D.Y., Weber J.D., and Gutmann D.H. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. Cancer Res. 65 (2005) 2755-2760
6. Johannessen C.M., Reczek E.E., James M.F., Brems H., Legius E., and Cichowski K. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc. Natl. Acad. Sci. USA 102 (2005) 8573-8578
7. Sawyers C.L. Will mTOR inhibitors make it as cancer drugs?. Cancer Cell 4 (2003) 343-348
8. Thomas G.V., Tran C., Mellinghoff I.K., Welsbie D.S., Chan E., Fueger B., Czernin J., and Sawyers C.L. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat. Med. 12 (2006) 122-127
9. Cichowski K., Shih T.S., Schmitt E., Santiago S., Reilly K., McLaughlin M.E., Bronson R.T., and Jacks T. Mouse models of tumor development in neurofibromatosis type 1. Science 286 (1999) 2172-2176
10. Vogel K.S., Klesse L.J., Velasco-Miguel S., Meyers K., Rushing E.J., and Parada L.F. Mouse tumor model for neurofibromatosis type 1. Science 286 (1999) 2176-2179
11. Escudier B., Szczylik C., Eisen T., Stadler W.M., Schwartz B., Shan M., and Bukowski R.M. Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J. Clin. Oncol. 23 Suppl 16S (2005) 4510
12. Demetri G.D., van Oosterom A.T., Garrett C.R., Blackstein M.E., Shah M.H., Verweij J., McArthur G., Judson I.R., Heinrich M.C., Morgan J.A., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 368 (2006) 1329-1338
13. Ratain M.J., Eisen T., Stadler W.M., Flaherty K.T., Kaye S.B., Rosner G.L., Gore M., Desai A.A., Patnaik A., Xiong H.Q., et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24 (2006) 2505-2512
14. Guba M., von Breitenbuch P., Steinbauer M., Koehl G., Flegel S., Hornung M., Bruns C.J., Zuelke C., Farkas S., Anthuber M., et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat. Med. 8 (2002) 128-135
15. Phung T.L., Ziv K., Dabydeen D., Eyiah-Mensah G., Riveros M., Perruzzi C., Sun J., Monahan-Earley R.A., Shiojima I., Nagy J.A., et al. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell 10 (2006) 159-170
16. Hudson C.C., Liu M., Chiang G.G., Otterness D.M., Loomis D.C., Kaper F., Giaccia A.J., and Abraham R.T. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol. Cell. Biol. 22 (2002) 7004-7014
17. Majumder P.K., Febbo P.G., Bikoff R., Berger R., Xue Q., McMahon L.M., Manola J., Brugarolas J., McDonnell T.J., Golub T.R., et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat. Med. 10 (2004) 594-601
18. Pantuck A.J., Thomas G., Belldegrun A.S., and Figlin R.A. Mammalian target of rapamycin inhibitors in renal cell carcinoma: Current status and future applications. Semin. Oncol. 33 (2006) 607-613
19. Brown R.S., Leung J.Y., Kison P.V., Zasadny K.R., Flint A., and Wahl R.L. Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. J. Nucl. Med. 40 (1999) 556-565
20. Sarbassov D.D., Ali S.M., Sengupta S., Sheen J.H., Hsu P.P., Bagley A.F., Markhard A.L., and Sabatini D.M. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22 (2006) 159-168
21. O'Reilly K.E., Rojo F., She Q.B., Solit D., Mills G.B., Smith D., Lane H., Hofmann F., Hicklin D.J., Ludwig D.L., et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66 (2006) 1500-1508
22. Rosen N., and She Q.B. AKT and cancer-is it all mTOR?. Cancer Cell 10 (2006) 254-256
23. Dorrello N.V., Peschiaroli A., Guardavaccaro D., Colburn N.H., Sherman N.E., and Pagano M. S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science 314 (2006) 467-471
24. Easton J.B., and Houghton P.J. mTOR and cancer therapy. Oncogene 25 (2006) 6436-6446
25. Kim H.A., Ratner N., Roberts T.M., and Stiles C.D. Schwann cell proliferative responses to cAMP and Nf1 are mediated by Cyclin D1. J. Neurosci. 21 (2001) 1110-1116
26. Costa L.J. Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin's lymphoma. Cancer Treat. Rev. 33 (2007) 78-84